Jefferies initiated coverage of Acuren (TIC) with a Buy rating and $16 price target The company is positioned to boost EBITDA margins due to cost synergies from the NV5 acquisition, operating leverage, and business improvements, the analyst tells investors in a research note. The firm views Acuren’s $20M NV5 cost synergy target as conservative.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TIC: